Ghent University
BactoRelief
Confidential
Frequent
Cough
Respiratory
Infections
Shortness of
Breath
General
Fatigue
02
Bronchiectasis
Ghent University
BactoRelief
The problem
Live Biotherapeutic Product (LBP)
- Defined consortium of "natural" live bacteria
03
Ghent University
BactoRelief
The Solution
- Synergism compared to individual species
- Prevent or treat pathological inflammation
Ghent University
BactoRelief
04
Formulation containing LBP
Freeze-drying
Product
Chronic lung
inflammation ↓
Nebulization
Saline
The Solution
Ghent University
BactoRelief
05
High unmet clinical need
1,163,411 patients in US, UK, Germany
Projected market growth
(965,8 million USD by 2031)
Market opportunity of BactoRelief
Ghent University
BactoRelief
Status of technology
08
% inflammation
Ghent University
BactoRelief
Status of technology
09
Ghent University
BactoRelief
Status of technology
10
Ghent University
BactoRelief
Status of technology
11
Freeze-dried formulation
with cryoprotectans
Long-term storage
(up to 1 year)
Nebulization
Ghent University
BactoRelief
Roadmap
13
IOF Stepstone
Seed Funding (6-7M)
Series a Funding
Lead LBP to candidate LBP
Candidate LBP to first-in-human
Investment
ready
IND
ready
Start
first-in-human trials
BactoRelief
Launch of
Jan
2025
Jan
2027
Jan
2029
BactoRelief Deck_Eurofins
By Ghent University
